Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.

Abstract

Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-α-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. It is important to be aware of such a serious complication since persistent bone marrow aplasia can be fatal. We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis.

• Authors: Naba R Mainali, Vijaya R Bhatt, Shiksha Kedia, Jairam Krishnamurthy, Laura M Wake, Mojtaba Akhtari
• Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (J Oncol Pharm Pract) Vol. 20 Issue 5 Pg. 386-92 (Oct 2014) ISSN: 1477-092X [Electronic] England
• PMID: 24067929 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: © The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Chemical References

• Antineoplastic Agents
• Interferon-alpha
• Recombinant Proteins
• Polyethylene Glycols
• peginterferon alfa-2a

Topics

• Antineoplastic Agents (adverse effects)
• Biopsy
• Bone Marrow (drug effects, pathology)
• Bone Marrow Diseases (chemically induced, diagnosis)
• Bone Marrow Examination
• Female
• Humans
• Interferon-alpha (adverse effects)
• Middle Aged
• Polyethylene Glycols (adverse effects)
• Primary Myelofibrosis (diagnosis, drug therapy)
• Recombinant Proteins (adverse effects)
• Treatment Outcome